High prevalence of hypothyroidism and hyperthyroidism to escalate demand for endocrine testing

 

The endocrine system consists of an intricate network of glandular structures that secreted hormones that regulate many important body processes, such as the body's capability to convert fats into energy which powers living tissues and organs, and the rate at which cells are replaced after injury or disease. Many diseases have been linked to endocrine dysfunctions and include breast cancer, diabetes, obesity, Alzheimer's, and multiple sclerosis. Endocrine disorders can be caused by exposure to toxins such as cigarette smoke, certain chemicals and pesticides, stress, infection, hormones, drugs, and radiation. Tumors can also cause endocrine problems as well, although very few tumors have been found to contain hormones and/or endocrine stimulating agents. Endocrine dysfunctions can cause hormonal imbalance, which can affect the pituitary gland which directly controls hormone production

 

The rising prevalence of endocrine disorders such as hyperthyroidism is primarily driving the growth of endocrine testing market. Moreover, the growing geriatric population is another key factor increasing the prevalence of hyperthyroidism which in turn augmenting the growth of endocrine testing market. According to the World Health Organization, by 2050, the world’s population aged 60 years and older is expected to total 2 billion, up from 900 million in 2015. By 2050, there will be almost this many (120 million) living in China alone, and 434 million people in this age group worldwide. By 2050, 80% of all older people will live in low- and middle-income countries. Also, growing advancement in the technologies such as easy-to-operate test kits which are user-friendly and cost-effective is again further projected to foster the market growth.

North America is expected to gain significant growth over the forecast period and this is attributed to the high prevalence of hypothyroidism and hyperthyroidism in the region. According to the U.S. Department of Health and Human Services, about 4.6 percent of the U.S. population ages 12 and older has hypothyroidism, although most cases are mild. That’s almost 5 people out of 100.

Key Developments:

1. In December 2019, the professional associations France Chimie, the FEBEA and the Fondation de la Maison de la Chimie, in partnership with the French Ministry of Ecological and Solidarity Transition, announce the creation of PEPPER, a public-private platform designed to develop research on the identification of endocrine disruptors

2. In November 2020, Institut national de la recherche scientifique (INRS) announce the creation of the Intersectoral Centre for Endocrine Disruptors Analysis (ICEDA), a new center devoted to the analysis of endocrine disruptors.

What is Lyme disease? What are the major symptoms and treatment available in market today?

 

Lyme disease or Lyme's disease is caused by the spirochete Borrelia burgdorferi. Commonly reported symptoms include severe headache, fever, dizziness, skin rash resembling eczema, and a severe infection with bacteria called erythrochocystitis. Complications may include joint damage, brain inflammation, paralysis, nerve damage, and permanent eye damage. Lyme disease is usually diagnosed by symptoms, behavioral findings (i.e., rash, muscle pain), and possible exposure to infected tick bites.

The growing prevalence of Lyme disease is a prime factor fueling market growth. An increase in the healthcare expenditure for improving medical services is driving the market growth. According to the World Health Organization, the global spending on the healthcare sector was US$ 7.8 trillion in 2017 or about 10% of GDP and $1,080 per capita – up from US$ 7.6 trillion in 2016. Rising awareness regarding Lyme disease around the globe is another major factor augmenting the market growth of the Lyme disease diagnostics market. An increasing number of research and development activities coupled with favorable government support is further projected to foster the market growth of the Lyme disease diagnostics market.

North America is expected to gain significant growth over the forecast period and this is attributed to the high prevalence of Lyme disease in the region. According to the U.S. Environmental Protection Agency, approximately 20,000–30,000 confirmed cases of Lyme disease per year. Also, the presence of well-established healthcare infrastructure coupled with the increasing investment by the government in the healthcare sector is further anticipated to propel the regional market growth.

Key Developments:

1. In November 2020, Galaxy Diagnostics, Inc., the provider of testing solutions for elusive flea and tick-borne pathogens, announced the launch of the Nanotrap® Urine Test for Lyme Borreliosis.

2. In July 2020, Adaptive Biotechnologies Corp. announced the launch of ImmuneSense Lyme™, a research study to inform the development of an improved test to detect Lyme disease in the early stages of infection, when the disease is most treatable but often missed or misdiagnosed.

3. In May 2020, The French biotech Valneva collaborated with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate.

4. In June 2019, QIAGEN and DiaSorin announced the expansion of their QuantiFERON collaboration to develop an ultra-sensitive diagnostic test for Lyme disease, which is projected to address a significant unmet medical need.

5. In April 2020, Valneva SE, a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) announced a partnership to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

Global PET Bottles Market Continues to Grow as Industry Leader Gerresheimer AG Expands its Production Capacity for Pharmaceutical Packaging in Changzhou, China

 

PET bottles have changed the way soft drinks are packaged and marketed over the past twenty years. PET is considered to be one of the most versatile and cost-efficient plastic products. It can be used in a wide range of applications, including high-volume shipping applications, flexible packaging applications, food packaging applications, dental applications, automotive applications, and industrial applications. The large volume production of PET as a packaging material has enabled manufacturers to use a uniform manufacturing process to produce a consistent product with excellent quality. PET has the ability to maintain its dimensional stability at room temperature, which results in its application in a wide range of applications.

 Increasing demand from the food & beverage industry is expected to drive growth of the global PET bottles market during the forecast period. The food and beverage industry has expanded significantly over the years with rising urbanization and higher inclination towards convenience food. According to the Ministry of Food Processing Industries, India, the food and beverage industry in India is expected to reach US$ 1.42 trillion by 2025, increasing from US$ 369 billion in 2017. According to the Food & Drink Federation (FDF), in 2018, total sales of manufactured food and drink reached over US$ 90 billion in the U.K. The food and beverage industry is the largest end-use industry of PET packaging bottles. These bottles are used to package various products including ketchup, cola, sodas, sauce, syrups, juice, fruit concentrates, etc. Thus, these factors are expected to drive growth of the PET bottles market during the forecast period. Moreover, continuous technological advancements in PET packaging are expected to boost the global PET bottles market growth over the forecast period.

However, fluctuations in raw material prices and environmental concerns regarding the use of plastics are expected to hinder the global PED bottles market growth over the forecast period. Advent of eco-friendly and recycled PET bottles can present lucrative growth opportunities in the global PET bottles market in the near future. Among regions, Asia Pacific is expected to witness significant growth in the global PET bottles market during the forecast period. This is owing to increasing demand from Japan, China, and India. Furthermore, North America is expected to register a robust growth rate over the forecast period, owing to high growth of pharmaceutical sector where PET bottles are used for the packaging of medicines.

Key companies involved in the global PET bottles market are Alpha Packaging, Cospack America Corporation, CKS Packaging Inc., Gerresheimer AG, Bericap GmbH & Co. KG, Alpack Plastic Packaging, Plastipak Holdings Inc., Berry Global Inc., Graham Packaging Company, Amcor Ltd., and Comar LLC.

For instance, in December 2019, Gerresheimer AG inaugurated a new plant for the production of pharmaceutical primary plastic packaging in Changzhou, China

Increasing Incidence of Cancer Worldwide to Boost the Theranostics Market Growth

 

Theranostics (a combination of therapeutics and diagnostics) is a new field of medicine that relies on targeted therapies to conduct specific tests. This includes a combination of targeted diagnostic tests with targeted therapies. Implementation of theranostics in patient care plan may turn into personalized therapy, which could further improve medical outcomes. It is widely used for various forms of cancers. Moreover, it is known to improve diagnosis, drug delivery, and treatment response monitoring. Theranostics offers a transition from traditional medicine to a modern personalized and precision medicine approach.

 

The increasing prevalence or incidence of cancer worldwide and the increasing need for theranostics is expected to drive the theranostics market growth. The global cancer burden is estimated to have risen to 18.1 million new cases in 2018. Cancer is the second leading cause of death worldwide, with an estimated 9.6 million deaths in 2018, according to the World Health Organization (WHO). Liver, stomach, colorectal, prostate, and lung cancer are the most common types of cancer in men, while thyroid, cervical, lung, colorectal, and breast cancer are the most common among women. A precisely targeted approach and accurate dose calibration can highly be useful in the management of chronic diseases such as cancer.

Moreover, the development of novel diagnostic tests coupled with available treatment options is expected to aid the theranostics market growth. For example, in September 2019, Mayo Clinic received the U.S. Food and Drug Administration (FDA) approval to use a positron emission tomography radiochemistry facility in Florida. Moreover, in 2017, Illumina launched an FDA approved sequencing cancer companion diagnostic test kit that helps identify patients with colorectal cancer. Furthermore, the rising adoption of companion diagnostic tests is also expected to augment the theranostics market. For instance, in July 2018, BloodCenter of Wisconsin started offering Abbott RealTime IDH1 assay that identifies specific gene mutations in patients with acute myeloid leukemia (AML).

In terms of geography, the theranostics market is divided into six regions, such as North America, Europe, Asia Pacific, South America, the Middle East, and Africa. North America and the Asia Pacific are expected to witness robust growth in the market due to the increasing awareness about companion diagnostic tests, increasing adoption of these tests, development activities, and collaborations by leading manufacturers in these regions. For instance, in August 2018, Qiagen collaborated with SRL to initiate new companion diagnostics with new drug approvals. Moreover, Novartis collaborated with the U.S.-based Biopharmaceutical Company, Endocyte, which develops targeted therapeutics for cancer treatment.

Electric wheelchairs emerging as one of the high-quality and advanced mobility device in healthcare sector

 

Electric wheelchairs, also known as electric powered wheelchair, manual wheelchair, or electrical wheelchair, any movable seating surface with no wheels attached to it which is powered by an electrical power source, usually batteries and motors. Batteries power electric wheelchairs by producing small amounts of electricity which are stored in rechargeable nickel-metal hydride batteries, which can be recharged when they are discharged.

Growing cases of physical disability is a key factor driving the market growth of the electric wheelchair. According to the World Health Organization, over 1 billion people are estimated to live with some form of disability. This corresponds to about 15% of the world's population, with up to 190 million (3.8%) people aged 15 years and older having significant difficulties in functioning, often requiring healthcare services. An increasing number of accidents around the globe leading to injuries and disability is also projected to augment the market growth of the electric wheelchair. According to the same source, every year the lives of around 1.35 million people are cut short as a result of a road traffic crash. Between 20 and 50 million more people suffer non-fatal injuries, with many incurring a disability as a result of their injury.

 

North America is expected to exhibit significant growth over the forecast period and this is attributed to the continuous product innovation by key manufacturers in the region. For instance, in March 2020, Invacare Corporation announced the launch of the Invacare® AVIVA™ FX Power Wheelchair, setting a new standard for the front-wheel-drive power mobility market.

Key Developments:

1. In August 2019, Droom has launched the electric wheel chair category on its platform. Along with the electric wheelchair, Droom has also launched products like mobility scooters and manual wheelchair on its platform.

2. In August 2020, A Chennai based startup, IIT-M has developed a personalized wheelchair and a battery-powered clip-on device that converts the wheelchair into a roadworthy electric vehicle.

3. In May 2019, ANA and Panasonic partner to test self-driving electric wheelchairs for increasing mobility and accessibility options at Tokyo Narita International Airport.

4. In January 2017, WHILL, the intelligent personal electric vehicles (EVs) provider, presents its new FDA-cleared electric vehicle wheelchair, the Model M, at the 2017 Consumer Electronics Show

5. In January 2020, Italian multinational firm Enel, through its energy services subsidiary Enel X, has announced the launch of its first device to charge electric wheelchairs with car charging infrastructure.

Global Buprenorphine Market Continues to Expand as Teva Pharmaceuticals Receives the U.S. FDA Clearance for Generic Version of Narcan Indicated for Opioid Overdose

 

Buprenorphine was developed as an opioid agonist, which is a type of partial agonist. It has been shown to effectively relieve pain and the discomfort caused by various kinds of withdrawal, such as that caused by drug addiction. Buprenorphine can be used as an extended-release (ER) drug. This type of drug allows the patient to have more control over their dosage and therefore to be able to continue with the program longer than would be possible with a shorter term (conventional) heroin or morphine analog. It is also believed to reduce dependence on the drug, as compared to other opioids such as oxycodone and hydrocodone. Buprenorphine belongs to the family of narcotics, along with codeine and hydrocodone, and is a derivative of codeine. It is available in different formulations such as tablets, liquids, powders, and injection devices. 

 

Increase in opioid epidemic in the U.S. is expected to drive growth of the global buprenorphine market during the forecast period. The opioid epidemic refers to the misuse or overuse of addictive opioid drugs with significant social, medical, and economic consequences such as death due to overdose. According to the U.S. Department of Health and Human Services, in 2018, around 10.3 million people aged 12 years and above misused opioids. According to the same source, around 9.9 million people misused prescription pain relievers, while 808,000 people used heroin. Moreover, in 2016, the national rate of opioid-associated hospitalization was 297 per 100,000 population. Buprenorphine is mainly used in the treatment of an opioid-related disorder. It can be administered intravenously, as a skin patch, or keeping it under the tongue. Thus, these factors are expected to drive growth of the global buprenorphine market during the forecast period. Moreover, the presence of a large number of buprenorphine manufacturers is expected to propel the global buprenorphine market growth over the forecast period.

However, side-effects related to buprenorphine such as dizziness, fever, tremors, sweating, diarrhea, and nausea are expected to hinder the global buprenorphine market growth over the forecast period. Among regions, North America is expected to witness significant growth in the global buprenorphine market during the forecast period. This is owing to stringent policies by government authorities to control the crisis of the opioid epidemic. Furthermore, an awareness campaign by the government is expected to boost the regional market growth in the near future.

Key companies involved in the global buprenorphine market are Faran Shimi Pharmaceutical Co., Siegfried, Micro Orgo Chem, Sanofi, Rusan Pharma, Johnson Matthey, Sun Pharmaceutical Industries Ltd., Johnson Matthey, Noramco, Resonance-labs, Mallinckrodt, Teva Pharmaceutical Industries Ltd., Arevipharma GmbH, and Unichem Laboratories.

For instance, in June 2019, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for the first generic version of Narcan, naloxone hydrochloride nasal spray indicated for opioid overdose.

Advancement in the biotechnology sector has positively shaped the alkaline proteases industry

 

Alkaline proteases are a type of enzyme that is active from neutral to pH range. An enzyme is any living thing that can be defined as a chemical reaction that changes something else, usually making a change in its shape or composition at some point during the catalytic reaction. The catalytic reaction may be a kinetic one - that is, it changes something because of the energy produced - or it may be a metabolic one - that is, it changes something because of the energy available for the catalytic reaction. Basically, an enzyme performs a number of functions: breaking down complex molecules into simple substances, assembling amino acids into peptide chains, playing a role in metabolism, and so on.

 

The expanding biotechnology industry due to technological advancement is driving the market growth of alkaline proteases. The rise in the investment in research &development activities is again expected to augment market growth. High demand for proteases from the soaps & detergents industry is also projected to foster the growth of alkaline proteases market . Growing hygiene awareness and increasing demand for the food industry for the preparation of food products is also projected to propel the market growth. Furthermore, the growing demand for environmentally friendly products across emerging economies and increasing use of proteases as therapeutic agents is further projected to augment the growth of alkaline proteases market .

From the geographical point of view, North America is expected to gain significant growth over the forecast period and this is attributed to the expansion of the pharmaceutical industry in the region. Increasing investment in the research and development activities is again expected to foster the regional market growth of the alkaline proteases. According to Pharmapproach Limited., in 2019, the United States remained the world’s largest single pharmaceutical market, generating more than $490 billion of revenue. Despite being only a 0.2% increase from the previous fiscal year, the United States market accounted for 48 percent of the global pharmaceutical market.

Key Developments:

In June 2020, Royal DSM, a global science-based company active in Nutrition, Health and Sustainable Living, announces the launch of its Delvo®Plant range of enzymes for optimizing the taste, texture and sweetness of plant-based drinks.

Key Players:

1. Ab Enzymes

2. Acumedia Manufacturers, Inc.

3. Advanced Enzymes

4. Novozymes

5. Noor Enzymes

6. Royal DSM

7. Sigma Aldrich Corporation

8. Solvay Enzymes

9. Specialty Enzymes & Biotechnologies Co.

High Prevalence of Osteonecrosis to Augment Growth of Osteonecrosis Treatment Market

 

Osteonecrosis is a medical term meaning "bone death." It is caused by an inflammation of the hip joint due to a reduction in blood supply. This type of bone disease can have an extensive impact on the quality of life of individuals suffering from it, making the treatment of osteonecrosis extremely important.

Market Dynamics

High prevalence of osteonecrosis is expected to propel growth of the osteonecrosis treatment market. For instance, according to the study, ‘Epidemiology of osteonecrosis among older adults in Sweden’, published in Springer in January 2019, the 10-year risk of osteonecrosis was 0.4% and the incidence rate was 4.7 cases/10000 person-years. Moreover, high prevalence of osteoporosis is also expected to aid in growth of the osteonecrosis treatment market. For instance, according to a study published online in February 2020 in the Journal of Clinical Endocrinology & Metabolism, for denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events (OPEs), including dental implants, tooth extraction, natural tooth loss, scaling/root planning, and jaw surgery, are common and associated with osteonecrosis of the jaw.

 

High prevalence of cancer is expected to offer lucrative growth opportunities for players in the osteonecrosis treatment market. For instance, in December 2020, a study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and published in JAMA Oncology, found that 2.8 percent of patients on average develop osteonecrosis of the jaw, within three years of starting a common treatment for cancer that has spread to the bone. Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.

Among regions, North America is expected to witness significant growth in the osteonecrosis treatment market, owing to high prevalence of cancer. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Competitive Analysis

Major players operating in the osteonecrosis treatment market include, Bone Health, Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd.

Major players operating in the osteonecrosis treatment market are focused on approval and launch of new products to expand their product portfolio. For instance, in December 2020, Bone Health’s OsteoBoost received the U.S FDA’s Breakthrough Device Designation to reduce the risk of osteoporosis.

In-depth Report on Osteonecrosis Market by Coherent Market Insights:

https://www.coherentmarketinsights.com/ongoing-insight/osteonecrosis-treatment-market-1490

Nonalcoholic Steatohepatitis Treatment Market is Witnessing Massive Traction as Ionis Pharmaceuticals, Inc. Continues its R&D with another Investigational Drug

 

Nonalcoholic Steatohepatitis (NASH) is an inflammation of the lower portion of the small intestine that includes the stomach and the duodenum. It is the most common digestive disease in the United States and is one of several types of the disease known as a fatty liver. Although the exact cause of this condition is not known, it is believed to be related to excessive amounts of insulin resistance or the lack of a sufficient level of the enzyme lipase. This condition does not present any symptoms but exists until the liver is able to properly digest and process insulin and lipid molecules. The treatment options for NASH are usually limited to anti-lipase agents and the restriction of carbohydrate intake. However, recently researchers have discovered that the consumption of green tea may be beneficial in treating and preventing the symptoms of NASH.

 

Rising incidence of nonalcoholic fatty liver disease (NAFLD) is expected to drive growth of the global nonalcoholic steatohepatitis treatment market during the forecast period. According to the American Liver Foundation (ALF), around 100 million individuals in the U.S. are expected to have NAFLD. According to the BMJ Journals, cases of NAFLD increasing from 391.2 million in 1990 to 882.1 million in 2017. According to the same source, the prevalence rate increased from 8.2% to 10.9% during the same period. Nonalcoholic steatohepatitis is a part of NAFLD and thus, the demand for treatment options is increasing rapidly. Hence, these factors are expected to drive growth of the global nonalcoholic steatohepatitis market during the forecast period. Furthermore, continuous research and development activities are expected to boost the global nonalcoholic steatohepatitis market growth over the forecast period.

However, a lack of effective medications and treatment options is expected to restrain growth of the global nonalcoholic steatohepatitis market during the forecast period. Among regions, North America is expected to witness significant growth in the global nonalcoholic steatohepatitis market during the forecast period. This is owing to proactive government initiatives and increasing cases of chronic diseases such as cancer and diabetes across the region. According to the American Diabetes Association (ADA), in 2018, around 34.2 million Americans had diabetes. Furthermore, Asia Pacific is expected to register a robust growth rate over the forecast period, owing to increasing R&D expenditure by key market players.

Key competitors operating in the global nonalcoholic steatohepatitis market are GE Healthcare, Agilent Technologies, Abbott Diagnostics, EUSA Pharma, BioCurex, Inc., Eli Lilly & Co., Biomarker Technologies, LLC, CytoCore, Inc., Ionis Pharmaceuticals, Inc., and Bruker Daltonics, Inc.

For instance, in November 2020, Ionis Pharmaceuticals, Inc. introduced the third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH).

What is Sodium Hexametaphosphate and its various applications across different industries?

 

Sodium Hexametaphosphate (SHMP)), also known as sodium seatmate, is a white crystalline salt of the chemical compound sodium hexametaphosphate (NAP). It is commonly used as an oxidizing agent in industries. It was first identified in a paper by Walraven and coworkers in 1947. This compound is used in some industrial and commercial paints and its general function is to prevent corrosion. However, there are other important industrial uses and these other uses are not touched upon here. Among the other uses of Sodium, hexametaphosphate is as an oxidizing agent for aluminum alloys and other metal salts, and as an additive to gasoline and diesel engine exhausts, and as an additive to paint formulations. It is also used as a corrosion inhibitor in some cutting and drilling operations.

The growing need for eco-friendly industrial processes and expansion of the various manufacturing industries are fueling the growth of Sodium hexametaphosphate market . Increasing demand for Sodium hexametaphosphate from water treatment plants due to the increasing instance of water pollution is again propelling the market growth. The rise in the food &beverage industry due to increasing spending and growing consumption of convenience food products is also projected to augment the market growth. It is used as an emulsifier, thickener, or texturizer in the food industry. According to the Economic Research Service United States Department of Agriculture, in 2019, U.S. consumers, businesses, and government entities spent $1.77 trillion on food and beverages in grocery stores and other retailers and on away-from-home meals and snacks.

The Asia Pacific is expected to gain significant growth over the forecast period and this is attributed to increasing demand for the product from the water treatment industry due to the growing instance of water pollution. Also, the increasing population in the region is again driving demand for clean water. The Asia and the Pacific region is home to 60 percent of the world’s population – some 4.3 billion people – and includes the world’s most populous countries, China and India. By 2050 the number of people aged 60 years and older in the region will more than double, reaching 1.3 billion.

Key Players:

1. Kraft Chemical Company, Inc.

2. Aditya Birla Chemicals, Prayon, Innophos

3. Chongqing Chuandong Chemical (Group) Co., Ltd

4. ICL, TKI Hrastnik, d.d.

5. Recochem Inc.

6. Hubei Xingfa Chemicals Group Co., LTD

7. Weifang Huabo Chemical Co., Ltd.

8. WeiKu

9. Xuzhou Tianjia Food Chemical Co., Ltd

10. Guizhou Sino-Phos Chemical Co., LTD.

11. Sichuan Blue Sword Chemical (Group) Co., Ltd.

12. Mianyang Aostar Phosphorus Chemical Industry

Increase in Medical Emergencies and Physical Injuries to Boost the Emergency Medical Equipment Market Growth

Emergency medical equipment is an integral part of the healthcare industry. It includes specialized products and equipment to assist in the provision of emergency care. Emergency medical equipment help in monitoring patients in uncontrolled environments in a pre-hospital setting. Several medical emergencies and physical injuries such as trauma are life-threatening and require quick medical attention. Thus, the increasing incidence of medical emergencies and trauma injuries create significant growth opportunities for the market. In the United States, around 3 million non-fatal injuries occur each year, causing more than 150,000 deaths, according to the American Association for the Surgery of Trauma.

 The geriatric population is more prone to various medical emergencies such as respiratory diseases, cardiac arrest, and other medical urgency. According to the World Health Organization, the world's population aged 60 years and older is expected to total 2 billion by 2050, up from 900 million in 2015. Today, 125 million people are aged 80 years or older. Moreover, increasing demand for emergency medical equipment and well-established healthcare facilities are also expected to drive the emergency medical equipment market growth. However, improper functioning (leads to product recall) and the high cost of equipment is expected to restrain the market growth.

Based on type, the market can be classified into patient handling equipment, infection control supplies, wound care consumables, emergency resuscitation equipment, patient monitoring systems, personal protection equipment, and others. Moreover, recent improvements in critical patient care and sudden infectious outbreaks, including COVID-19, will contribute to the tremendous demand for emergency medical equipment. As of December 23, the virus has infected more than 78 million people worldwide, and thus, the demand for emergency medical equipment from COVID-19 affected countries has increased, driving the market growth. Various efforts and initiatives are being taken by organizations and industry leaders to meet the unprecedented need.

Technological advancements coupled with infrastructure development, as well as increasing government funding, is also expected to increase the demand for such equipment. In terms of geography, the emergency medical equipment market is divided into six regions, such as North America, Europe, Asia Pacific, South America, the Middle East, and Africa. Key players active in the market are adopting various strategies (such as product launch, mergers and acquisition, etc.) to strengthen their market presence. For example, in April 2020, Stryker launched emergency relief beds to provide efficient care solutions during the pandemic. Moreover, in June 2018, Royal Phillips acquired Remote Diagnostic Technologies to strengthen its market presence in the resuscitation and emergency care industry.

Increasing Prevalence of Asthma to Augment Growth of Pulmonary Drug Delivery Systems Market

 

Pulmonary drug delivery via nanoparticles has shown great potential in treating patients who are highly pretreated for chronic conditions like asthma, chronic obstructive pulmonary disease (COPD), or lung cancer. Nanoparticles can be a perfect way to deliver therapeutic drugs that demonstrate suppressed solubility in pulmonary blood secretions. In regular oral administration, multiple droplets of drug are free from drug and others are densely filled with the drug at high concentrations, directing to good circulation and distribution of the drug throughout the body. But when the drug is released into the pulmonary circulation, solute concentrations drop drastically as a result of water droplets clogging the air ways.

Market Dynamics

Increasing prevalence of asthma is expected to propel growth of the global pulmonary drug delivery systems market. For instance, according to The Global Asthma Report 2018, around 300 million people have asthma worldwide, and the number is expected to reach 100 million by 2025.

 

Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global pulmonary drug delivery systems market. For instance, globally, as of 9:39am CET, 22 December 2020, there have been 76,023,488 confirmed cases of COVID-19, including 1,694,128 deaths, reported to the World Health Organization.

Moreover, increasing number of clinical trials for development of new drugs is also expected to aid in growth of the market. For instance, in December 2020, TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced dosing of the first subjects in its Phase 1b clinical trial of Voriconazole Inhalation Powder, a next-generation, direct-to-lung, inhaled dry powder version of voriconazole, which is generally considered to be the most effective antifungal drug for treatment of Aspergillosis infections.

Competitive Analysis

Major players operating in the global pulmonary drug delivery systems market include, 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., Philips Healthcare, and Liquidia Technologies, Inc.

Major players operating in the global pulmonary drug delivery systems market are focused on approval and launch of new products to expand their product portfolio. For instance, in November 2020, Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation, announced that the U.S. Food and Drug Administration has issued a complete response letter for the company’s New Drug Application for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension.

In-depth Report on Pulmonary Drug Delivery Systems Market by Coherent Market Insights:

https://www.coherentmarketinsights.com/market-insight/pulmonary-drug-delivery-systems-market-3952

High Prevalence of Genetic Disorders and Cancer to Augment Growth of Antisense Oligonucleotides Market

 

Antisense oligonucleotides (ASOs) are modified single-stranded DNA molecules used in the regulation of unsuitable expression of genes in pathological situations by the specific inhibition of expression of their mRNA targets. ASOs are used for the treatment of spinal muscular atrophy, Duchenne muscular dystrophy, and other genetic disorders.

Market Dynamics

High prevalence of cancer is expected to propel growth of the antisense oligonucleotides market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

 Increasing investment in R&D of cancer is expected to offer lucrative growth opportunities for players in antisense oligonucleotides market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19. Moreover, high prevalence of genetic disorders is also expected to aid in growth of the market. For instance, according to the study, ‘Carrier frequency of SMN1-related spinal muscular atrophy in north Indian population: The need for population based screening program’ published in American Journal of Medical Genetics in October 2020, the carrier frequency of Spinal Muscular Atrophy (SMN)1 deletion was 1 in 38 (16 out of 606).

Absence of large clinical trials confirming the promising results obtained with antisense oligonucleotides in preclinical models is expected to hinder growth of the antisense oligonucleotides market.

Competitive Analysis

Major players in operating in the antisense oligonucleotides market include, Ionis Pharmaceuticals Inc., Aligos Therapeutics, Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc., Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation, Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and Rxi Pharmaceuticals Inc.

Major players in operating in the antisense oligonucleotides market are focused on adopting partnership strategies to enhance their market share. For instance, in December 2020, Aligos Therapeutics, Inc. entered into an Exclusive License and Research Collaboration Agreement with Merck, under which Merck and Aligos will apply Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis (NASH) target and up to one additional target of interest in the cardiometabolic/fibrosis space.

In-depth Report on Antisense Oligonucleotides Market by Coherent Market Insights:

https://www.coherentmarketinsights.com/ongoing-insight/antisense-oligonucleotides-market-1879

How personal care packaging is evolving the cosmetic and personal care industry?

 

Personal care packaging is done primarily for different items like soaps, shampoos, cosmetics, body lotions, oil, and others. Basically, it is packaged in the same form as other packaged items with different materials, such as paperboard, plastics, metal, glass, wood, and many others, and packed. Personal Care Packaging is usually made from cardboard (but more nowadays with recyclable material to reduce waste) and uses strong glue for its packing. The concept of personal care packaging is becoming more important because of the shift to 'buy local' and 'try local'. At present, 'green' or sustainable packaging is the current trend of the times and people are beginning to look for eco-friendly and sustainable packaging even for everyday items they use at home or in their daily lives.

Changing fashion trend as personal care products is driving the market growth of the personal care packaging. The growing disposable income of the consumer is also expected to increase the sale of personal care products which is again driving demand for personal care packaging. Increasing working women across developing countries coupled with the growing hygiene awareness among consumers is also projected to foster the market growth of the personal care packaging. The increasing population and growing focus of the manufacturer to improve the aesthetic value of the product is further anticipated to accelerate the market growth of the personal care packaging over the forecast period. 

 

Europe is expected to gain significant growth over the forecast period and this is attributed to the strong presence of the personal care &cosmetic industry in the region. Also, high awareness regarding the cosmetic brands among women is again anticipated to propel the regional market growth over the forecast period. According to the Cosmetics Europe, The Personal Care Association, the European cosmetics, and personal care market is the largest in the world it was valued at €79.8 billion at a retail sales price in 2019. The largest national markets for cosmetics and personal care products within Europe includes Italy (€10.5 billion), France (€11.4 billion), Germany (€14 billion), the UK (€10, 7 billion), Spain (€7.1 billion) and Poland (€4.1 billion).

Key Developments:

1. In April 2020, Kao launched a new sustainable personal care line MyKirei in the USA. The new line is launched on Amazon. Inspired by the “Kirei philosophy”, the products come into an eco-friendly “ground-breaking” bottle using up to 50% less plastic and offer biodegradable plant-based formulas.

2. In December 2020, bluemarlin, a brand acceleration agency, has entered into a partnership with ITC’s Personal Care Products Business to help support and deliver design and branding solutions for its health and hygiene flagship brands Nimyle and Salvon.

Dyes, Pigments, Paints, and Coatings Market Growing Rapidly as Key Industry Leader DIC Corporation Completes Acquisition of BASF SE’s Global Pigment Business

 

Pigments are substances that react with air to form color. Pigments may be oil-based or water-based, organic or inorganic, metallic or non-metallic, or fluorescent. There are also a variety of applications for pigments and dyes. Pigments and dyes are used in a wide range of applications, including manufacturing, chemistry, art, industry, electronics, furniture, textiles, cosmetics, and medical technology. Some pigments and dyes have their own applications and properties. Some pigments, like the popular blue pigment, are widely used in tattoos. A coating refers to covering applied on the surface of an object used for decorative, functional, or both purposes. 

 

Continuous research and development activities by market players are expected to drive growth of the global dyes, pigments, paints, and coatings market during the forecast period. Key market players across the globe are focused on research and development activities, in order to innovate novel products. For instance, in March 2020, researchers from New Zealand Institute for Plant and Research discovered a new class of pigments called auronidins. According to the researchers, this discovery is capable of creating more stable and intensely colored natural pigments for CPG products. Furthermore, in June 2019, DyStar introduced a new portfolio of eco-friendly products to help the textile value chain. Thus, these factors are expected to drive growth of the global dyes, pigments, paints, and coatings market during the forecast period. Moreover, rising demand from the textile industry is expected to boost the global dyes, pigments, paints, and coatings market growth over the forecast period.

However, increasing demand for digital printing in the textile industry combined with the negative impact of COVID-19 outbreak is expected to hamper the global dyes, pigments, paints, and coatings market growth over the forecast period. Besides, high demand from end-use industries and increasing technological advancements can provide lucrative growth opportunities in the global dyes, pigments, paints, and coatings market in the near future. Among regions, Asia Pacific is expected to witness significant growth in the global dyes, pigments, paints, and coatings market growth over the forecast period. This is owing to favorable manufacturing conditions and ease in regulatory frameworks across the region. Moreover, Europe is expected to register a robust growth rate in the dyes, pigments, paints, and coatings market over the forecast period. This is owing to increasing demand for dyes and pigments in the region.

Key players operating in the global dyes, pigments, paints, and coatings market are Altana AG, Venator Materials PLC, BASF SE, The Chemours Company, Clariant, Merck KGaA, DIC CORPORATION, DuPont, Kiri Industries Limited, Sudarshan Chemical Industries Limited, and Flint Group.

For instance, in August 2019, DIC Corporation, a chemicals company, acquired BASF’s global pigments business.

High Prevalence of Ovarian Cancer to Augment Growth of Ovarian Cancer Drugs Market

 

Treatment for ovarian cancer normally involves a combination of chemotherapy and surgery. Chemotherapy uses special medicines to kill or shrink the cancer cells. Drugs used to treat ovarian cancer are considered systemic therapies.

Market Dynamics

High prevalence of ovarian cancer is expected to propel growth of the ovarian cancer drugs market. For instance, the National Cancer Institute estimated around 22,530 new cases of ovarian cancer and 13,980 deaths due to the disease in the U.S. in 2019. Moreover, availability of effective drugs is also expected to aid in growth of the market. For instance, in October 2020, according to a new research conducted by scientists at the Fox Chase Cancer Center and Gynecologic Oncology Group, a targeted medication known as bevacizumab, also going by the name Avastin, may delay the development of advanced ovarian cancer.

R&D in ovarian cancer is expected to offer lucrative growth opportunities for players in the ovarian cancer drugs market. For instance, in June 2020, a study presented via the virtual Society of Gynecologic Oncology 2020 Annual Meeting on Women's Cancer, reported examining a large clinical dataset of low-grade serous ovarian cancer through the Ovarian Cancer Association Consortium, with the primary goal of identifying factors that affect survival.

 

However, development of vaccines is expected to hinder growth of the ovarian cancer drugs market. For instance, in December 2020, Anixa Biosciences entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an ovarian cancer vaccine technology.

Major players operating in the ovarian cancer drugs market are focused on R&D to expand their product portfolio. For instance, in December 2020, TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, announced positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors in ovarian cancer.

Competitive Analysis

Major players operating in the ovarian cancer drugs market include, Bristol Myers Squibb Company, Eli Lilly and Company, IMV Inc., TCR2 Therapeutics Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd.

Major players operating in the ovarian cancer drugs market are focused on R&D to expand their product portfolio. For instance, in December 2020, IMV Inc., a clinical-stage biopharmaceutical company, reported updated clinical and translational data from DeCidE1, its Phase 2 clinical study evaluating the safety and efficacy of DPX-Survivac with intermittent low-dose cyclophosphamide (CPA) in patients with recurrent, advanced platinum-sensitive and platinum-resistant ovarian cancer.

In-depth Report on Ovarian Cancer Drugs Market by Coherent Market Insights:

https://www.coherentmarketinsights.com/ongoing-insight/ovarian-cancer-drugs-market-164

Ongoing trend of go-green is boosting sale of renewable chemicals

 

Renewable chemicals are chemicals derived from eco-friendly products such as corn, biomass, algae, and sugarcane. These chemicals can be transformed into various useful products like fertilizers, antifreeze, gasoline, fuel, synthetic rubbers, and plastics, etc. These chemicals have wide applications in different sectors including food & beverages, agriculture, forestry, petrochemical, cosmetics, pharmaceutical, and others. In general, these chemicals can be categorized into two categories as synthetic and bio-organic chemicals.

Growing preferences for eco-friendly products coupled with the low-cost of the feedstock is driving the market growth of renewable chemicals. Increasing prices of fossil fuels and the need to reduce greenhouse emissions are again contributing to the market growth of renewable chemicals. Moreover, the growing cultivation of corn and sugarcane as they are the ideal substitute for renewable chemicals is further projected to accelerate the market growth over the forecast period. According to the International Sugar Organization, sugarcane, on average, accounts for nearly 80% of global sugar production. Between 2001 and 2018, world sugar consumption increased from 123.454 mln tones to 172.441 mln tones, the equivalent to average annual growth of 2.01%. Also, the growing popularity of biopolymers derived from renewable feedstock such as corn and sugarcane is further anticipated to foster the market growth of renewable chemicals over the forecast period.

North America is expected to gain significant growth over the forecast period and this is attributed to increasing initiatives by the government to promote the use of eco-friendly products. For instance, the US Environmental Protection Agency (EPA) has made it compulsory for the manufacturer of gasoline to use a percentage of renewable ethanol, as ethanol significantly reduces greenhouse gas emissions.

Key Developments:

1. In July 2020, Praj Industries foray into developing technologies to produce bio-based renewable chemicals and materials (RCM). RCM produced from bio-based feedstocks are sustainable alternatives to products made from fossil resources.

2. In October 2020, Perstorp announced the launch of the first partly renewable carboxylic acids - 2-Ethylhexanoic Acid Pro and Valeric Acid Pro. 2-EHA Pro is based on 25% renewable raw materials, and Valeric Acid Pro contains 20% renewable content.

3. In October 2019, Clariant has partnered with renewable hydrocarbon producer Neste to offer a wide range of additives based on mass balance certified ethylene and propylene from renewable feedstock, which reliably delivers both high performance and sustainability.

4. In August 2018, Braskem launches a new renewable resin made from sugarcane in Allbirds shoes. It is designed for the application such as footwear, automotive, transportation, and others.

Increasing sale of electronic gadgets to expand market size of graphene

 

Graphene is a super-advanced material that has many useful qualities. It is widely used in electronics products, photovoltaic cells, ultra-light vehicles, energy generation systems, and medical implants. It is a unique combination of diamond and graphite, with the best of both worlds. Graphenes has extraordinary strength and stiffness. Diamond is brittle by nature, while Graphene is much more so, which opens up a whole new class of products and applications. Graphene is classified into mono-layer & bi-layer graphene, graphene oxide (GO), few-layer graphene (FLG), and graphene nanoplatelets (GNP).

 

 

High demand for consumer electronic products such as tablets and mobile phones due to increasing disposable income is predominantly fueling the market growth of graphene. Expansion of the chemical industry around the globe is another key factor augmenting the market growth of graphene. According to the Cefic Facts & Figures 2020, the global chemicals turnover was valued at €3,347 billion in 2018. Global sales grew by 2.5% from €3,266 billion in 2017 to €3,347 billion in 2018. With €1,198 billion in 2018, China is still the largest chemical producer in the world, contributing 35.8% of global chemical sales in 2018.

The Asia Pacific is expected to exhibit significant growth over the forecast period and this is attributed to the increasing usage of consumer electronic products in the region. According to the India Brand Equity Foundation, the Indian appliance and consumer electronics (ACE) market reached Rs. 76,400 crore (US$ 10.93 billion) in 2019. Appliances and the consumer electronics industry is expected to double to reach Rs. 1.48 lakh crore (US$ 21.18 billion) by 2025.

Key Developments:

1. In November 2020, Graphene announced the launch of the next generation of advanced technologies, and the Stirling based outfit, Integrated Graphene is set to launch their first graphene-enhanced product

2. In November 2020, Applied Graphene Materials, a producer of specialty graphene nanoplatelet dispersions, has launched a new commercial service offering. ‘Innovation Accelerator’ is a unique end-to-end research and development service to support businesses in harnessing the potential of graphene in their products.

3. In October 2020, GrapheneCA has developed a new graphene-improved ceramic-based coating with a built-in antimicrobial additive for protection of various types of glass for up to 2 years.

4. In July 2019 Graphmatech has launched Aros Create which is Nylon Aros Graphene® pellets with a volume resistivity of less than 1 Ωcm while maintaining polymer lightweight, flexibility, processability, and recyclability.

Global Endometrial Ablation Market Continues to Expand as U.S.-based Company Minerva Surgical completes acquisition of Boston Scientific’s Intrauterine Health franchise

 

Endometrial Ablation is a medical procedure that is used to either eliminate (abate) or disintegrate (disintegrate) the endometrial tissue of the uterus in patients who regularly have very heavy menstrual periods. There are three procedures that are commonly used for this procedure: Single-cell ablation, selective leucoplast, and laparoscopy-assisted ablation. Endometrial Ablation may also be referred to as "endometrium ligation". This is the name given to the procedure when a small hole is made in the outermost layer of the endometrial cells. Endometrial Ablation usually takes longer than other methods and can be painful for some women. Some patients report feeling pressure and pain in the abdominal area, pelvic area, or in the lower back while having the procedure.

 

Increasing number of various gynecological disorders is expected to drive growth of the global endometrial ablation market during the forecast period. The incidence of gynecological disorders such as ovarian cysts, pelvic pain, uterine cancer, vagina skin disorders, etc. has increased significantly. According to the Centers for Disease Control and Prevention (CDC), between 2012 and 2016 around 94,000 women were diagnosed with gynecologic cancer each year in the U.S. According to the same source, the most gynecologic cancer was uterine cancer with 26.82 cases per 100,000. Such a high incidence of uterine cancer, which causes vaginal bleeding after menopause and bleeding between periods has increased the adoption of endometrial ablation. Thus, these factors are expected to drive growth of the global endometrial ablation market during the forecast period. Moreover, increasing demand for minimally invasive surgical procedures is expected to boost the global endometrial ablation market growth over the forecast period.

However, an unfavorable regulatory framework combined with high costs related to ablation procedures is expected to hinder the global endometrial ablation market growth over the forecast period. Besides, the lack of reimbursement policies is expected to hamper the market growth in the near future. Among regions, North America is expected to witness significant growth in the global endometrial ablation market during the forecast period. This is owing to rapid technological advancements and the presence of robust healthcare infrastructure across the region. Moreover, Asia Pacific is expected to exhibit a lucrative growth rate over the forecast period, owing to increasing accessibility to novel endometrial ablation procedures in the region.

Key companies involved in the global endometrial ablation market are Boston Scientific Corporation, The Cooper Companies Inc., Olympus Corporation, Smith & Nephew, Minerva Surgical, Inc., Karl Storz GmbH & Co. KG, Richard Wolf GmbH, Ethicon, LLC, and Medtronic plc.

For instance, in May 2020, Minerva Surgical, a U.S.-based healthcare company, acquired Boston Scientific’s Intrauterine Health franchise with a commitment to eliminate Abnormal Uterine Bleeding (AUB).